Clinical Trial Search

Primary: Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success — 62.6; 36.0 percentage of participants

Primary: Percentage of Participants With Clinical Cure at Test of Cure (TOC) in Participants With HAP/VAP/HCAP or BSI/Sepsis — 50.0; 52.6; 43.5; 42.9 percentage of participants

Primary: Overall Survival (OS) — 21.4; 14.3 months — p=0.0005

Primary: Sustained Virologic Response (SVR) — 10; 10 Participants

Primary: Seroprotection Rate (SPR) = Percentage of Participants Who Have a Seroprotective Immune Response — 204; 198 Participants

Primary: The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12 — 18.38; 14.53 Lesions — p=<0.0001

Primary: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) — 0.94; 1.86 Events/year — p=<0.0001

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 20 — -0.13; -0.02; -1.03; 0.57 Percentage

Primary: Overall Improvement Rate for the Target Lesion — 86; 89 Participants — p=0.120

Primary: Overall Response Rate (ORR) — 19.2; 20.9 percentage of participants

Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants

Primary: Number of Subjects With mRS Score of 0 to 2 — 329; 337 Participants — p=0.335

Primary: Change From Baseline to Week 12 in Maturation Value (MV) After 12 Weeks of Treatment — 26.9; 3.2 vaginal health index — p=<0.001

Primary: Average Duration of Fever. — 3.1; 3.6 days — p=0.0174

Primary: Number of Participants With ≥1 New Vertebral Fracture Since Study BA058-05-003 Baseline — 3; 25 Participants